{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-122952","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-11-05T11:04:15+00:00","discovered_at":"2026-11-05T11:10:00.294313+00:00","generated_at":"2026-11-05T11:11:11.451815+00:00","sec_items":["2.02","3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cognition Therapeutics gets Nasdaq bid-price deficiency notice; Q3 net loss narrows to $4.1M","bullets":["Nasdaq deficiency letter dated Nov. 3, 2026: CGTX closing bid below $1.00 for 30 consecutive business days; 180 days to May 3, 2027 to regain compliance.","No immediate delisting; shares continue trading on Nasdaq Capital Market. Company may get a second 180-day period and could use a reverse stock split to cure.","Q3 2026 net loss $4.1M, or $(0.04) per share, vs $4.9M, or $(0.06), in Q3 2025; R&D rose to $5.1M from $3.8M.","Cash and restricted cash $31.5M at Sept. 30, 2026, plus $18.2M obligated NIA grant funds; runway estimated into Q4 2027.","FDA aligned on Phase 3 endpoints for zervimesine (CT1812) in dementia with Lewy bodies; Phase 2 START topline expected in 2H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-122952","json":"https://secwatch.observer/filing/0001104659-26-122952.json","markdown":"https://secwatch.observer/filing/0001104659-26-122952.md","text":"https://secwatch.observer/filing/0001104659-26-122952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926122952/0001104659-26-122952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926122952/tm2629072d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-05T11:11:11.451815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}